Pharmacological receptors: A century of discovery - and more

Pharmaceutica Acta Helvetiae

Volumn 74, Issue 2-3, 2000, Pages 79-84

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Drug receptor interactions; Emil Fischer; John Newton Langley; Louis Pasteur; Paul Ehrlich; Receptor diseases; Receptor history; Receptor regulation; Receptor structure; Receptors; Stereoselectivity

Indexed keywords

CELL NUCLEUS RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; ION CHANNEL;

CONFERENCE PAPER; DRUG DEVELOPMENT; GENETIC ANALYSIS; GENETIC DISORDER; HISTORY; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RECEPTOR BINDING; RESEARCH; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL;

ANIMALS; HISTORY, 20TH CENTURY; HUMANS; PHARMACOLOGY; RECEPTORS, DRUG;

EID: 0034109517     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(99)00046-1     Document Type: Conference Paper

References (31)

1. Ackerman M.J., Clapham D.E. Ion channels - basic science and clinical disease. N. Engl. J. Med. 336:1997;1575-1586.
2. Belelli D., Pau D., Cabras G., Peters J.A., Lambert J.J. A single amino acid confers barbiturate sensitivity upon the GABA p1 receptor. Br. J. Pharmacol. 127:1999;601-604.
3. Bikker J.A., Trumpp-Kallmeyer S., Humblet C. G-Protein coupled receptors: models, mutagenesis and drug design. J. Med. Chem. 41:1998;2911-2927.
4. Buscher R., Herrmann V., Inel P.A. Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Trends Pharmacol. Sci. 20:1999;94-99.
5. Civelli O., Nothacker H.-P., Reinscheid R. Reverse physiology: discovery of the novel neuropeptide, orphanin FQ/nociceptin. Crit. Rev. Neurobiol. 12:1998;163-176.
6. Cooper E.C., Jan L.Y. Ion channel genes and human neurological disease: recent progress, prospects, and challenges. Proc. Natl. Acad. Sci. U S A. 96:1999;4759-4766.
7. Cushny, A.R., 1926. Biological Relations of Optically Isomeric Substances. Balliere, Tindall and Cox, London.
8. + conduction and selectivity. Science. 280:1998;69-74.
9. Ehrlich P. On immunity with special reference to cell life. Proc. R. Soc. London. 125:1900;424-449.
10. Farfel Z., Bourne H.R., Iiri T. Mechanisms of disease: the expanding spectrum of G protein diseases. N. Engl. J. Med. 340:1999;1012-1020.
11. Fischer E. Einfliuss der konfiguration auf die wirkung der enzyme. Ber. Dtsch. Chem. Ges. 27:1894;2985-2993.
12. Greer J., Erickson J.W., Baldwin J.J., Varney M.D. Application of the three-dimensional structures of protein target molecules - structure-based drug design. J. Med. Chem. 37:1994;1035-1054.
13. Holladay M.W., Dart M.J., Lynch J.K. Neuronal nicotinic receptors as targets for drug discovery. J. Med. Chem. 40:1997;4169-4194.
14. Ingelman-Sundberg M., Oscarson M., McLellan R.A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20:1999;342-349.
15. Keating M.T., Sanguinetti M.C. Pathophysiology of ion channel mutations. Current Biology. 6:1996;326-333.
16. Kleyn P.W., Vessell E.S. Genetic variation as a guide to drug development. Science. 281:1998;1820-1821.
17. Langley J.N. On nerve endings and on special excitable substances in cells. Proc. R. Soc. London, Ser. B. 78:1906;170-184.
18. Mann, J., 1992. Murder Magic and Medicines. Oxford Univ. Press, Oxford.
19. Moody E.J., Harris B.D., Skolnick P. The potential for safer anesthesia using stereoselective anesthetics. Trends Pharmacol. Sci. 15:1994;387-390.
20. 1B receptors. Nature. 360:1992;161-163.
21. Parascondola J. The theoretical basis of Paul Ehrlich's chemotherapy. J. Hist. Med. 36:1981;19-43.
22. Pasteur, L., 1860. On the asymmetry of naturally occurring compounds (Two lectures delivered before the Chemical Society of Paris, 20th of January and 3rd of February, 1860). In: Richardson, G.M. (Ed.), Memoirs of Stereochemistry. American Book, London, 1901, pp. 1 - 33.
23. Robertson D.W., Willy P.J. Nuclear orphan receptors: scientific progress and therapeutic opportunities. Annu. Rep. Med. Chem. 32:1997;251-260.
24. Rudolph U., Mohler H. Genetically modified animals in pharmacological research: future trends. Eur. J. Pharmacol. 375:1999;327-337.
25. 1-subunits. Soc. Neurosci. Abstr. 24:1998;1990. cited in Rudolph and Mohler (1999).
26. Sedensky M.M., Cascorbi H.F., Meinwald J., Radford P., Morgan P.G. Genetic differences affecting the potency of stereoisomers of halothane. Proc. Natl. Acad. Sci. U S A. 91:1994;10054-10058.
27. Siffert W., Rosskopf D., Siffert G.et al. Association of a human G-protein (beta)3 subunit variant with hypertension. Nature Genetics. 18:1998;45-48.
28. Soontjens C.D., Rafter J.J., Gustafsson J.-A. Ligands for orphan receptors? J. Endocrinol. 150:1996;S241-S257.
29. Spiegel A.M. Defects in G protein-coupled signal transduction in human disease. Annu. Rev. Physiol. 58:1995;143-170.
30. Weatherall, M., 1990. In Search of a Cure. Oxford Univ. Press, Oxford, UK.
31. Wilson S., Bergsma D.K., Chambers J.K., Muir A.I., Fantom K.G.M., Ellis C., Murdock P.R., Herrity N.C., Stadel J.M. Orphan G-protein-coupled receptors: the next generation of drug targets? Br. J. Pharmacol. 125:1998;1387-1392.